DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 8,883,146 B2 Fraunhofer Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 8,883,146 B2 Fraunhofer Et Al USOO8883146 B2 (12) United States Patent (10) Patent No.: US 8,883,146 B2 Fraunhofer et al. (45) Date of Patent: *Nov. 11, 2014 (54) PROTEINFORMULATIONS AND METHODS (56) References Cited OF MAKING SAME U.S. PATENT DOCUMENTS (71) Applicant: AbbVie Inc., North Chicago, IL (US) 4,597,966 A 7/1986 Zolton et al. 4,877,608 A 10, 1989 Lee et al. (72) Inventors: Wolfgang Fraunhofer, Gurnee, IL (US); 5,237,054 A 8, 1993 Brinks et al. Annika Bartl, Ludwigshafen (DE); 5,608,038 A 3, 1997 Eiblet al. Hans-Juergen Krause, Biblis (DE); 5,702,699 A 12/1997 Hanish et al. Markus Tschoepe, Hessheim (DE); 6,090,382 A T/2000 Salfeld et al. Katharina Kaleta, Ludwigshafen (DE) 6,165.467 A 12/2000 Hagiwara et al. 6,171,586 B1 1/2001 Lam et al. 6,252,055 B1 6/2001 Relton (73) Assignee: AbbVie Inc., North Chicago, IL (US) 6,258,562 B1 7/2001 Salfeld et al. 6,281,336 B1 8/2001 Laursen et al. (*) Notice: Subject to any disclaimer, the term of this 6,436,397 B1 8/2002 Baker et al. patent is extended or adjusted under 35 6,485,932 B1 1 1/2002 McIntosh et al. U.S.C. 154(b) by 0 days. 6,509,015 B1 1/2003 Salfeld et al. 6,693,173 B2 2/2004 Mamidi et al. This patent is Subject to a terminal dis- 7,070,775 B2 7/2006 Le et al. claimer. 7,223,394 B2 5/2007 Salfeld et al. 7,250,165 B2 7/2007 Heavner et al. (21) Appl. No.: 13/774,735 7,276,239 B2 10/2007 Le et al. 7,541,031 B2 6/2009 Salfeld et al. (22) Filed: Feb. 22, 2013 7,588,761 B2 9/2009 Salfeld et al. 7,758,860 B2 7/2010 Warne et al. (65) Prior Publication Data 7,863,426 B2 1/2011 Wan et al. 7.919,264 B2 4/2011 Maksymowych et al. US 2013/0156760 A1 Jun. 20, 2013 8,034,906 B2 10/2011 Borhani et al. 8,092,998 B2 1/2012 Stuhlmuller et al. 8,093,045 B2 1 2012 Pla et al. Related U.S. Application Data 8, 187,836 B2 5, 2012 Hsieh (63) Continuation of application No. 12/325,049, filed on 8, 197,813 B2 6/2012 Salfeld et al. Nov. 28, 2008, now Pat. No. 8,420,081. (Continued) (60) Provisional application No. 61/004,992, filed on Nov. FOREIGN PATENT DOCUMENTS 30, 2007. EP 0486526 5, 1992 (51) Int. Cl. EP 419251 B 1, 1993 A 6LX39/395 (2006.01) (Continued) A6 IK39/00 (2006.01) A6 IK38/00 (2006.01) OTHER PUBLICATIONS C07K 16/00 (2006.01) C07K 6/24 (2006.01) Abbott “Humira Prescribing Info..”. Jan. 31, 2003.* CI2P 2/08 (2006.01) A6 IK9/00 (2006.01) (Continued) A6 IK9/08 (2006.01) 3. I 3.08: Primary Examiner — Robert Landsman A6 IK38/46 (2006.01) Assistant Examiner — Bruce D Hissong A6 IK38/48 (2006.01) (74) Attorney, Agent, or Firm — McCarter & English LLP: A6 IK38/50 (2006.01) Cristin H. Cowles; Deborah L. Nagle C07K L/34 (2006.01) (52) U.S. Cl. CPC ........... A61K.39/3955 (2013.01); A61 K9/0019 (57) ABSTRACT (2013.01); A61K 9/08 (2013.01); A61 K9/19 (2013.01); A61 K38/21 (2013.01); A61 K38/46 The invention provides an aqueous formulation comprising (2013.01); A61K 38/4893 (2013.01); A61 K water and a protein, and methods of making the same. The 38/50 (2013.01); A61K.39/395 (2013.01); aqueous formulation of the invention may be a high protein A61K.39/39591 (2013.01); C07K I/34 formulation and/or may have low levels of conductity result (2013.01) ing from the low levels of ionic excipients. Also included in USPC ... 424/130.1; 424/145.1: 514/1.1 : 530/387.1; the invention are formulations comprising water and proteins 530/388.23 having low osmolality. (58) Field of Classification Search None See application file for complete search history. 18 Claims, 36 Drawing Sheets US 8,883,146 B2 Page 2 (56) References Cited 2007/0237762 A1 10, 2007 Winter 2007/0244.299 A1 10, 2007 Jaber U.S. PATENT DOCUMENTS 2007/0253984 A1 11/2007 Khandke et al. 2007/02694.63 A1 11/2007 Donovan et al. 8,206,714 B2 6, 2012 Salfeld et al. 2007,0292442 A1 12/2007 Wan et al. 8,216,583 B2 7/2012 Kruase et al. 2008.0003220 A1 1/2008 Gokarn 8,231,876 B2 7/2012 Wan et al. 2008, 0071063 A1 3, 2008 Alan et al. 8,372.400 B2 2/2013 Salfeld et al. 2008. O112953 A1 5/2008 McAuley et al. 8,372.401 B2 2/2013 Salfeld et al. 2008.0118496 A1 5/2008 Medich et al. 8,414,894 B2 4/2013 Salfeld et al. 2008/O124326 A1 5/2008 Rehder et al. 8.420,081 B2 4/2013 Fraunhofer et al. 2008. O1313.74 A1 6/2008 Medich et al. 8.436,149 B2 5, 2013 Borhani et al. 2008/O139792 A1 6/2008 Seket al. 2003, OO12786 A1 1/2003 Teoh et al. 20080145383 A1 6/2008 Zauner et al. 2003/004.5454 A1 3f2003 Okumu et al. 2008.0161230 A1 7/2008 Jones et al. 2003/0138417 A1 7/2003 Kaisheva et al. 2008/0166348 Al 72008 Kupper et al. 2003/0143603 A1 7/2003 Giles-Komar et al. 2008/0193466 A1 8/2008 Banerjee et al. 2003/0161828 A1 8/2003. Abdelghany et al. 2008, 0200655 A1 8, 2008 Sek 2003/0180287 A1 9, 2003 Gombotz et al. 2008/0227136 Al 9, 2008 Pla et al. 2003/O190316 A1 10, 2003 Kakuta et al. 2008/0275220 A1 11/2008 FrieSS 2003/0206898 A1 11, 2003 Fischkoffetal. 2008/0280345 A1 11/2008 Turner et al. 2003/0219438 A1 11, 2003 Salfeld et al. 2008/0311043 A1 12/2008 Hoffman et al. 2003/0235585 A1 12, 2003 Fischkoffetal. 2008/0311078 A1 12/2008 Gokarn et al. 2004.0009172 A1 1/2004 Fischkoffet al. 2009, OO17472 A1 1/2009 Stuhlmuller et al. 2004/0028667 A1 2/2004 Norman et al. 2009/0028794 A1 1/2009 Medich et al. 2004/0033228 A1 2/2004 Krause et al. 2009.0054331 A1 2/2009 Chen et al. 2004/0038878 A1 2/2004 Tanikawa et al. 2009/006872 A1 3/2009 Kaymakcalan et al. 2004/0105889 A1 6/2004 Ryde et al. 2009/0110679 A1 4, 2009 Li et al. 2004/0126372 A1 7/2004 Banerjee et al. 2009/0123378 A1 5/2009 Wong et al. 2004/0126373 A1 7/2004 Banerjee et al. 2009, O1484.06 A1 6, 2009 Jezek 2004/O131614 A1 7/2004 Banerjee et al. 2009, O1485.13 A1 6/2009 Fraunhofer et al. 2004/O136989 A1 7/2004 Banerjee et al. 2009. O155205 A1 6/2009 Salfeld et al. 2004/O136990 A1 7/2004 Banerjee et al. 2009, 0226530 A1 9, 2009 Lassner et al. 2004/0136991 A1 7/2004 Banerjee et al. 2009/02392.59 Al 9, 2009 Hsieh et al. 2004/0151722 A1 8/2004 Banerjee et al. 2009,0258018 A1 10, 2009 Medich et al. 2004/01661 11 A1 8/2004 Kaymakcalan et al. 2009/0271164 Al 10/2009 Peng et al. 2004/0170623 A1 9, 2004 Arvinte et al. 2009,0280065 A1 11/2009 Willian et al. 2004/019 1243 A1 9/2004 Chen et al. 2009,0291062 A1 11/2009 Fraunhofer et al. 2004/O197324 A1 10, 2004 Liu et al. 2009/0304682 A1 12/2009 Hoffman et al. 2004/0213785 A1 10, 2004 Yamazaki et al. 20090317399 A1 12/2009 Pollack et al. 2004/0219142 A1 1 1/2004 Banerjee et al. 2010.0003243 A1 1/2010 Okun et al. 2004/0228913 A1 11/2004 Kumar et al. 2010, OO16557 A1 1/2010 Salfeld et al. 2005.0053598 A1 3, 2005 Burke et al. 2010/0021451 A1 1/2010 Wong et al. 2005, 0118163 A1 6/2005 Mizushima et al. 2010, 0028372 A1 2/2010 Jezek 2005, 0118167 A1 6, 2005 Okada et al. 2010, 0028383 A1 2/2010 Van Gelder et al. 2005/01 19172 A1 6, 2005 Merkle 2010.0034823 A1 2/2010 Borhani et al. 2005/0214278 A1 9, 2005 Kakuta et al. 2010.0040604 A1 2/2010 Salfeld et al. 2006/0009385 A1 1/2006 Hoffman et al. 2010.0040630 A1 2/2010 Elden et al. 2006, 0083741 A1 4/2006 Hoffman et al. 2010.0113744 A1 5, 2010 Tsvetkova et al. 2006, OO88523 A1 4/2006 Andya et al. 2010/0129379 A1 5/2010 Carpenter et al. 2006, O115472 A1 6, 2006 Li et al. 2010, 0160894 A1 6, 2010 Julian et al. 2006, O142549 A1 6, 2006 Takeda et al. 2010/0278822 A1 11/2010 Fraunhofer et al. 2006/0149042 A1 7/2006 Konstantinov et al. 2011/0014676 A1 1/2011 Cowan et al. 2006/0153846 A1 7/2006 Krause et al. 2011/0054414 A1 3/2011 Shang et al. 2006, O159653 A1 7, 2006 Saito et al. 2011/0171227 A1 7, 2011 Okun et al. 2006, O18274.0 A1 8/2006 Yang et al. 2011/0236391 A1 9, 2011 Mahler et al. 2006/0210557 A1 9, 2006 Luisi et al. 2011/0300151 A1 12/2011 Okun et al. 2006/0246073 Al 1 1/2006 Knight et al. 2012/00 14956 A1 1/2012 Kupper et al. 2006/02694.79 A1 11, 2006 Colton et al. 2012/0077213 A1 3/2012 Pla et al.
Load more

Recommended publications
  • Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 23 February 2012 (23.02.2012) WO 2U12/U24519ft ft A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US201 1/048297 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 18 August 201 1 (18.08.201 1) NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/374,943 18 August 2010 (18.08.2010) US kind of regional protection available): ARIPO (BW, GH, 61/441,485 10 February 201 1 (10.02.201 1) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 61/449,372 4 March 201 1 (04.03.201 1) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventor; and EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, (71) Applicant : DEISHER, Theresa [US/US]; 1420 Fifth LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Avenue, Seattle, WA 98101 (US).
    [Show full text]
  • Inclusion and Exclusion Criteria for Each Key Question
    Supplemental Table 1: Inclusion and exclusion criteria for each key question Chronic HBV infection in adults ≥ 18 year old (detectable HBsAg in serum for >6 months) Definition of disease Q1 Q2 Q3 Q4 Q5 Q6 Q7 HBV HBV infection with infection and persistent compensated Immunoactive Immunotolerant Seroconverted HBeAg HBV mono-infected viral load cirrhosis with Population chronic HBV chronic HBV from HBeAg to negative population under low level infection infection anti-HBe entecavir or viremia tenofovir (<2000 treatment IU/ml) Adding 2nd Stopped antiviral therapy antiviral drug Interventions and Entecavir compared Antiviral Antiviral therapy compared to continued compared to comparisons to tenofovir therapy therapy continued monotherapy Q1-2: Clinical outcomes: Cirrhosis, decompensated liver disease, HCC and death Intermediate outcomes (if evidence on clinical outcomes is limited or unavailable): HBsAg loss, HBeAg seroconversion and Outcomes HBeAg loss Q3-4: Cirrhosis, decompensated liver disease, HCC, relapse (viral and clinical) and HBsAg loss Q5: Renal function, hypophosphatemia and bone density Q6: Resistance, flare/decompensation and HBeAg loss Q7: Clinical outcomes: Cirrhosis, decompensated liver disease, HCC and death Study design RCT and controlled observational studies Acute HBV infection, children and pregnant women, HIV (+), HCV (+) or HDV (+) persons or other special populations Exclusions such as hemodialysis, transplant, and treatment failure populations. Co treatment with steroids and uncontrolled studies. Supplemental Table 2: Detailed Search Strategy: Ovid Database(s): Embase 1988 to 2014 Week 37, Ovid MEDLINE(R) In-Process & Other Non- Indexed Citations and Ovid MEDLINE(R) 1946 to Present, EBM Reviews - Cochrane Central Register of Controlled Trials August 2014, EBM Reviews - Cochrane Database of Systematic Reviews 2005 to July 2014 Search Strategy: # Searches Results 1 exp Hepatitis B/dt 26410 ("hepatitis B" or "serum hepatitis" or "hippie hepatitis" or "injection hepatitis" or 2 178548 "hepatitis type B").mp.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9.468,689 B2 Zeng Et Al
    USOO9468689B2 (12) United States Patent (10) Patent No.: US 9.468,689 B2 Zeng et al. (45) Date of Patent: *Oct. 18, 2016 (54) ULTRAFILTRATION CONCENTRATION OF (56) References Cited ALLOTYPE SELECTED ANTIBODES FOR SMALL-VOLUME ADMINISTRATION U.S. PATENT DOCUMENTS 5,429,746 A 7/1995 Shadle et al. (71) Applicant: Immunomedics, Inc., Morris Plains, NJ 5,789,554 A 8/1998 Leung et al. (US) 6,171,586 B1 1/2001 Lam et al. 6,187,287 B1 2/2001 Leung et al. (72) Inventors: Li Zeng, Edison, NJ (US); Rohini 6,252,055 B1 6/2001 Relton Mitra, Brigdewater, NJ (US); Edmund 6,676,924 B2 1/2004 Hansen et al. 6,870,034 B2 3/2005 Breece et al. A. Rossi, Woodland Park, NJ (US); 6,893,639 B2 5/2005 Levy et al. Hans J. Hansen, Picayune, MS (US); 6,991,790 B1 1/2006 Lam et al. David M. Goldenberg, Mendham, NJ 7,038,017 B2 5, 2006 Rinderknecht et al. (US) 7,074,403 B1 7/2006 Goldenberg et al. 7,109,304 B2 9, 2006 Hansen et al. 7,138,496 B2 11/2006 Hua et al. (73) Assignee: Immunomedics, Inc., Morris Plains, NJ 7,151,164 B2 * 12/2006 Hansen et al. ............. 530,387.3 (US) 7,238,785 B2 7/2007 Govindan et al. 7,251,164 B2 7/2007 Okhonin et al. (*) Notice: Subject to any disclaimer, the term of this 7.282,567 B2 10/2007 Goldenberg et al. patent is extended or adjusted under 35 7,300,655 B2 11/2007 Hansen et al.
    [Show full text]
  • WO 2015/028850 Al 5 March 2015 (05.03.2015) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2015/028850 Al 5 March 2015 (05.03.2015) P O P C T (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, C07D 519/00 (2006.01) A61P 39/00 (2006.01) BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, C07D 487/04 (2006.01) A61P 35/00 (2006.01) DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 31/5517 (2006.01) A61P 37/00 (2006.01) HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, A61K 47/48 (2006.01) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, PCT/IB2013/058229 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (22) International Filing Date: TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 2 September 2013 (02.09.2013) ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (26) Publication Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, (71) Applicant: HANGZHOU DAC BIOTECH CO., LTD UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, [US/CN]; Room B2001-B2019, Building 2, No 452 Sixth TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, Street, Hangzhou Economy Development Area, Hangzhou EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, City, Zhejiang 310018 (CN).
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
    bioRxiv preprint doi: https://doi.org/10.1101/572958; this version posted March 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title: Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories. Authors: Konrad Krawczyk1*, Matthew Raybould2, Aleksandr Kovaltsuk2, Charlotte M. Deane2 1 NaturalAntibody, Hamburg, Germany 2 Oxford University Department of Statistics, Oxford, UK *Correspondence to [email protected] Abstract: Recently it has become possible to query the great diversity of natural antibody repertoires using Next Generation Sequencing (NGS). These methods are capable of producing millions of sequences in a single experiment. Here we compare Clinical Stage Therapeutic antibodies to the ~1b sequences from 60 independent sequencing studies in the Observed Antibody Space Database. Of the 242 post Phase I antibodies, we find 16 with sequence identity matches of 95% or better for both heavy and light chains. There are also 54 perfect matches to therapeutic CDR-H3 regions in the NGS outputs, suggesting a nontrivial amount of convergence between naturally observed sequences and those developed artificially. This has potential implications for both the discovery of antibody therapeutics and the legal protection of commercial antibodies. Introduction Antibodies are proteins in jawed vertebrates that recognize noxious molecules (antigens) for elimination. An organism expresses millions of diverse antibodies to increase the chances that some of them will be able to bind the foreign antigen, initiating the adaptive immune response.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • The Two Tontti Tudiul Lui Hi Ha Unit
    THETWO TONTTI USTUDIUL 20170267753A1 LUI HI HA UNIT ( 19) United States (12 ) Patent Application Publication (10 ) Pub. No. : US 2017 /0267753 A1 Ehrenpreis (43 ) Pub . Date : Sep . 21 , 2017 ( 54 ) COMBINATION THERAPY FOR (52 ) U .S . CI. CO - ADMINISTRATION OF MONOCLONAL CPC .. .. CO7K 16 / 241 ( 2013 .01 ) ; A61K 39 / 3955 ANTIBODIES ( 2013 .01 ) ; A61K 31 /4706 ( 2013 .01 ) ; A61K 31 / 165 ( 2013 .01 ) ; CO7K 2317 /21 (2013 . 01 ) ; (71 ) Applicant: Eli D Ehrenpreis , Skokie , IL (US ) CO7K 2317/ 24 ( 2013. 01 ) ; A61K 2039/ 505 ( 2013 .01 ) (72 ) Inventor : Eli D Ehrenpreis, Skokie , IL (US ) (57 ) ABSTRACT Disclosed are methods for enhancing the efficacy of mono (21 ) Appl. No. : 15 /605 ,212 clonal antibody therapy , which entails co - administering a therapeutic monoclonal antibody , or a functional fragment (22 ) Filed : May 25 , 2017 thereof, and an effective amount of colchicine or hydroxy chloroquine , or a combination thereof, to a patient in need Related U . S . Application Data thereof . Also disclosed are methods of prolonging or increasing the time a monoclonal antibody remains in the (63 ) Continuation - in - part of application No . 14 / 947 , 193 , circulation of a patient, which entails co - administering a filed on Nov. 20 , 2015 . therapeutic monoclonal antibody , or a functional fragment ( 60 ) Provisional application No . 62/ 082, 682 , filed on Nov . of the monoclonal antibody , and an effective amount of 21 , 2014 . colchicine or hydroxychloroquine , or a combination thereof, to a patient in need thereof, wherein the time themonoclonal antibody remains in the circulation ( e . g . , blood serum ) of the Publication Classification patient is increased relative to the same regimen of admin (51 ) Int .
    [Show full text]
  • W W W .Bio Visio N .Co M
    Biosimilar Monoclonal Antibodies Human IgG based monoclonal antibodies (mAbs) are the fastest-growing category of therapeutics for cancer therapy. Several mechanisms of tumor cell killing by antibodies (mAbs) can be summarized as: direct action through receptor blockade or induction of apoptosis; immune-mediated cell killing by complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) or regulation of T cell function. Several monoclonal antibodies have received FDA approval for the treatment of a variety of solid tumors and hematological malignancies. BioVision is pleased to offer research grade biosimilars in human IgG format for your research needs. Our monoclonal antibodies are manufactured using recombinant technology with variable regions from the therapeutic antibody to achieve similar safety and efficacy. These antibodies can be used as controls for preclinical lead identification and potency assays for the development of novel therapeutics. Antibody Name Cat. No. Trade Name Isotype Size Anti-alpha 5 beta 1 Integrin (Volociximab), Human IgG4 Ab A1092 - IgG4 200 µg Anti-Beta-galactosidase, Human IgG1 Ab A1104 - IgG1 200 µg Anti-C5 (Eculizumab), Humanized Ab A2138 - IgG2/4 100 μg Anti-Carcinoembryonic antigen (Arcitumomab), Human IgG1 Ab A1096 - IgG1 200 µg Anti-CCR4 (Mogamulizumab), Human IgG1, kappa Ab A2005 - IgG1 200 μg Anti-CD11a (Efalizumab), Human IgG1 Ab A1089 Raptiva IgG1 200 µg Anti-CD20 (Rituximab), Chimeric Ab A1049 Mabthera IgG1 100 µg Anti-CD22 (Epratuzumab), Human IgG1 Ab A1445 LymphoCide IgG1 200 µg Anti-CD3 epsilon (Muromonab), Mouse IgG2a, kappa Ab A2008 - IgG2a 200 μg Anti-CD33 (Gemtuzumab), Human IgG4 Ab A1443 Mylotarg IgG4 200 µg Anti-CD38 (Daratumumab), Human IgG1 Ab A2151 Darzalex IgG1 100 μg www.biovision.com 155 S.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub
    US 20170172932A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2017/0172932 A1 Peyman (43) Pub. Date: Jun. 22, 2017 (54) EARLY CANCER DETECTION AND A 6LX 39/395 (2006.01) ENHANCED IMMUNOTHERAPY A61R 4I/00 (2006.01) (52) U.S. Cl. (71) Applicant: Gholam A. Peyman, Sun City, AZ CPC .......... A61K 9/50 (2013.01); A61K 39/39558 (US) (2013.01); A61K 4I/0052 (2013.01); A61 K 48/00 (2013.01); A61K 35/17 (2013.01); A61 K (72) Inventor: sham A. Peyman, Sun City, AZ 35/15 (2013.01); A61K 2035/124 (2013.01) (21) Appl. No.: 15/143,981 (57) ABSTRACT (22) Filed: May 2, 2016 A method of therapy for a tumor or other pathology by administering a combination of thermotherapy and immu Related U.S. Application Data notherapy optionally combined with gene delivery. The combination therapy beneficially treats the tumor and pre (63) Continuation-in-part of application No. 14/976,321, vents tumor recurrence, either locally or at a different site, by filed on Dec. 21, 2015. boosting the patient’s immune response both at the time or original therapy and/or for later therapy. With respect to Publication Classification gene delivery, the inventive method may be used in cancer (51) Int. Cl. therapy, but is not limited to such use; it will be appreciated A 6LX 9/50 (2006.01) that the inventive method may be used for gene delivery in A6 IK 35/5 (2006.01) general. The controlled and precise application of thermal A6 IK 4.8/00 (2006.01) energy enhances gene transfer to any cell, whether the cell A 6LX 35/7 (2006.01) is a neoplastic cell, a pre-neoplastic cell, or a normal cell.
    [Show full text]
  • L:\0901 with Peru\0901PHARMAPPX.Wpd
    Harmonized Tariff Schedule of the United States (2009) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2009) (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABAPERIDONE 183849-43-6 ACITAZANOLAST 114607-46-4 ABARELIX 183552-38-7 ACITEMATE 101197-99-3 ABATACEPT 332348-12-6 ACITRETIN 55079-83-9 ABCIXIMAB 143653-53-6 ACIVICIN 42228-92-2 ABECARNIL 111841-85-1 ACLANTATE 39633-62-0 ABETIMUS 167362-48-3 ACLARUBICIN 57576-44-0 ABIRATERONE 154229-19-3 ACLATONIUM NAPADISILATE 55077-30-0 ABITESARTAN 137882-98-5 ACODAZOLE 79152-85-5 ABLUKAST 96566-25-5 ACOLBIFENE 182167-02-8 ABRINEURIN 178535-93-8 ACONIAZIDE 13410-86-1 ABUNIDAZOLE 91017-58-2 ACOTIAMIDE 185106-16-5 ACADESINE 2627-69-2 ACOXATRINE 748-44-7 ACAMPROSATE 77337-76-9 ACREOZAST 123548-56-1 ACAPRAZINE 55485-20-6
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,258.268 B2 Wu Et Al
    USOO8258268B2 (12) United States Patent (10) Patent No.: US 8,258.268 B2 Wu et al. (45) Date of Patent: Sep. 4, 2012 (54) DUAL VARIABLE DOMAIN 5,624,821 A 4/1997 Winter et al. MMUNOGLOBULIN AND USES THEREOF 5,627,052 A 5/1997 Schrader et al. 5,641,870 A 6/1997 Rinderknecht et al. 5,648,260 A 7, 1997 Winter et al. (75) Inventors: Chengbin Wu, Shrewsbury, MA (US); 5,658,727 A 8, 1997 Barbas et al. Tariq Ghayur, Holliston, MA (US); 5,677,171 A 10, 1997 Hudziak et al. 5,679,377 A 10, 1997 Bernstein et al. Richard W. Dixon, Jefferson, MA (US); 5,693,762 A 12/1997 Queen et al. Jochen G. Salfeld, North Grafton, MA 5,698,426 A 12/1997 Huse et al. (US) 5,714,350 A 2f1998 CO et al. 5,714,352 A 2f1998 Jakobovits (73) Assignee: Abbott Laboratories, Abbott Park, IL 5,723,323 A 3, 1998 Kauffman et al. 5,733,743 A 3, 1998 Johnson et al. (US) 5,736,137 A 4, 1998 Anderson et al. 5,750,753 A 5/1998 Kimae et al. (*) Notice: Subject to any disclaimer, the term of this 5,763,192 A 6/1998 Kauffman et al. patent is extended or adjusted under 35 5,766,886 A 6/1998 Studnicka et al. 5,780,225 A 7/1998 Wigler et al. U.S.C. 154(b) by 0 days. 5,814,476 A 9, 1998 Kauffman et al. 5,817483. A 10, 1998 Kauffman et al.
    [Show full text]